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Fibrosis is one of the most prevalent features of age-related diseases like obesity, diabetes, non-alcoholic
fatty liver disease, chronic kidney disease, or cardiomyopathy and affects millions of people in all
countries. Although the understanding about the pathophysiology of ﬁbrosis has improved a lot during
the recent years, a number of mechanisms still remain unknown. Although TGF-β1 signaling, loss of
metabolic homeostasis and chronic low-grade inﬂammation appear to play important roles in the pa-
thogenesis of ﬁbrosis, recent evidence indicates that oxidative stress and the antioxidant system may also
be crucial for ﬁbrosis development and persistence. These ﬁndings point to a concept of a redox-ﬁbrosis
where the cellular oxidant and antioxidant system could be potential therapeutic targets. The current
review aims to summarize the existing links between TGF-β1 signaling, generation and action of reactive
oxygen species, expression of antioxidative enzymes, and functional consequences including epigenetic
redox-mediated responses during ﬁbrosis.
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Fibrosis is a major health problem and considered to be one of
the most prevalent features of age-related diseases affecting mil-
lions of people in all countries. It can be considered to be a non-
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where an excessive extracellular matrix (ECM) deposition leads to
irreversible tissue damage and failure or disturbance of proper
organ function. Fibrosis has been found to affect all major organs
and tissues including lungs, kidney, liver, heart, and skin. More-
over, the stroma of solid tumors can be considered to be partially
ﬁbrotic [1–4]. The pathophysiology of ﬁbrosis has generally been
studied in the context of the particular organ or tissue affected.
However, recent research on the underlying molecular mechan-
isms provided evidence that common aspects for initiation and
progression of ﬁbrosis appear to exist in each of the affected or-
gans/tissues. In particular, loss of metabolic homeostasis and
chronic low-grade inﬂammation appear to play new emerging
roles in the pathogenesis of ﬁbrosis. Recent evidence indicated
that oxidative stress, a condition where the balance between for-
mation of reactive oxygen species (ROS) and their degradation by
the antioxidant system is shifted in favor of a pro-oxidant state,
appears to link metabolic homeostasis and inﬂammation thereby
underpinning the concept of common ﬁbrosis pathways that could
be potential therapeutic targets. The current review aims to
summarize the role of ROS and especially the anti-oxidative en-
zymes in ﬁbrosis.Fig. 1. Fibroblasts as major extracellular matrix (ECM) producers. Fibroblasts can be
derived from different cells like vascular smooth muscle cells, pericytes, ﬁbrocytes,
endo-and epithelial cells or resident ﬁbroblasts. Depending on their origin these
cells undergo differentiation, poliferation, epithelial-to-mesenchymal transition
(EMT) or endothlial-to-mesenchymal transition (EndoMT). The so emerged myo-
ﬁbroblasts show an increased synthesis of matrix proteins contributing to excessive
ECM deposition and ﬁbrosis.2. Fibrosis: common features and aspects
Fibrogenesis is a dynamic process and was proposed to occur in
all organs in four common phases: i) initiation, due to injury of the
organ/tissue; ii) inﬂammation and activation of effector cells, iii)
enhanced synthesis of ECM; and iv) deposition of ECM with pro-
gression to end-organ failure [4]. The common aspects of a ﬁbrotic
pathogenesis can also be “visualized” because the same macro-
scopic and microscopic features are shared between the ﬁbrotic
organs. Macroscopically ﬁbrotic organs usually display an uneven
surface, are non-elastic, hard, and pale; signs resulting from ac-
cumulated ECM, contracted ﬁbroblasts and reduced vasculature.
Microscopically clear signs of an injured parenchyma, excess ap-
pearances of ﬁbroblasts and ﬁbrillar ECM, lack of capillaries (i.e.
microvasculature), and a mononuclear inﬁltrate can be visualized
[3]. Although there are obvious common elements in the ﬁbrotic
developments between organs, it appears that there are also some
differences, which account for some organ speciﬁc aspects which
become visible during the disease.3. Fibroblasts: key players during ﬁbrosis
The name ﬁbrosis is based on the very well and long-term
known observation that ﬁbroblasts are the major source of the
ECM; in ﬁbrosis ﬁbroblasts are called “activated ﬁbroblasts” or
“myoﬁbroblasts” due to their increased synthetic capacity. Al-
though the name “activated ﬁbroblasts” may also imply a higher
proliferative capacity, they are in fact less proliferative but more
metabolically active in particular in ECM production [5]. Moreover,
ﬁbroblasts are not homogenous; they were found to be hetero-
genous within single organs and also between organs [6]. The
heterogeneity may result, at least in part, from different cells and
modes used for ﬁbroblast recruitment/activation. While the most
common view considers that activated ﬁbroblasts derive via pro-
liferation from tissue resident ﬁbroblasts, various studies have
shown that bone marrow-derived ﬁbrocytes [7], endothelial cells
that have undergone endothelial-to-mesenchymal transition [8],
vascular smooth muscle cells and pericytes shed off from vessels
[9,10], and epithelial cells after epithelial-to-mesenchymal transi-
tion [11] are also able to contribute to ECM deposition and ﬁbrosis
(Fig. 1). This makes the molecular analysis of ﬁbroblastsparticularly challenging, and though α-smooth muscle actin, vi-
mentin, ﬁbroblast-speciﬁc protein 1, or desmin are used to identify
ﬁbroblasts, it may explain why a speciﬁc common marker for all
ﬁbroblasts has not been found yet (for review see [3] and [12]).
Moreover, processes like aging also affect the ﬁbroblast protein
expression proﬁles [13] which further complicates the molecular
analyses of ﬁbroblasts.4. Fibrosis, tissue injury and inﬂammation
Commonly the regenerative capacity of parenchymal cells is
able to cope with the loss of parenchyma occurring during single
tissue injury events. However, this regenerative ability is lost upon
repeated injury with the consequence of deregulated wound
healing and a chronic activation of the immune response with
appearing inﬂammation. Although ﬁbrosis and its associated in-
ﬂammation can be caused by infectious agents (e.g. viral infection
of the liver or bacterial infections of lungs and kidneys), in most
cases no underlying infection could be determined. This indicates
that the inﬂammation is due to other not yet fully understood
mechanisms, likely involving cell death responses [14,15]. Inter-
estingly, anti-inﬂammatory therapies are rather ineffective in the
treatment of ﬁbrosis suggesting a complex interplay between the
ﬁbroproliferative process and the inﬂammatory response where
pro- and retrograde cellular crosstalk of parenchymal cells, ﬁbro-
blasts, and immune cells needs to be differently considered (for
review see [16–18]).
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In addition to activation of ﬁbroblasts and immune cells, ﬁ-
brosis-inducing events also cause release of proﬁbrotic metabo-
lites (e.g., ROS), and secretion of chemokines and growth factors.
Increased evidence indicates that production of ROS and oxidative
stress are interlinked with production and activation of various
growth factors and cytokines [19–21]; thereby feed-back as well as
feed-forward cycles appear to exist (Fig. 2).
Indeed, increased levels of 4-hydroxy-2′-nonenal (4-HNE), a
marker of lipid peroxidation [22], have been detected in biopsy
samples from liver ﬁbrosis patients. In addition, 8-isoprostane,
another marker of oxidative stress, was found to be present in
exhalants and bronchoalveolar lavage ﬂuid from patients with
lung ﬁbrosis [23,24]. In particular ROS were supposed to play a key
role in the development of silicosis and asbestosis since nitro-
tyrosine adducts and indicators for enhanced oxidative DNA da-
mage like 8-hydroxy-2′-deoxyguanosine (8-OHdG) were found in
those patients [25,26]. Moreover, oxidative stress was shown to be
present during development of renal ﬁbrosis [27,28] as well as to
play a role in several aspects of ﬁbrotic cardiac repair/remodeling
after infarction [29–31].
5.1. Sources of ROS in ﬁbrosis
ROS can be produced either non-enzymatically or en-
zymatically. The major non-enzymatic triggers for ROS formation
in vivo are ionizing and UV radiation, toxic chemicals and drugs,
which all are well known inducers of ﬁbrosis in different organs.
While the majority of intracellular ROS is generated as by-products
of respiratory chain function, various enzymes such as xanthine
oxidoreductase (XOR), several peroxisomal oxidases, enzymes of
the cytochrome P450 family, cyclooxygenases, lipoxygenases, and
NADPH oxidases (NOX) were found to contribute to ROS produc-
tion (for review see [32].
From the enzymatic ROS producers NADPH oxidases appear to
be most important during the pathological progression of ﬁbrosis
[33,34] (Fig. 3). Production of O2̄ by the NOX complex in phago-
cytes is a well-known phenomenon of the oxidative burst involved
in bacteriocidal activity [35,36]. The heterodimeric transmem-
brane parts of the classical NOX complexes from phagocytes
consist of the NOX2 protein and NOX subunit p22phox. Up to now,
further NOX proteins have been identiﬁed and currently the NOXFig. 2. Feed-forward and feed-back events where ROS can contribute to ﬁbrosis In-
fection, injury, toxic chemicals, drugs as well as radiation (UV, ionizing) may lead to
formation of ROS. As a consequence ROS might directly contribute to ﬁbrosis or
indirectly via enhanced inﬂammation. Fibrosis itself may feedback to ROS forma-
tion or foster generation of cytokines and growth factors which also can contribute
to generation of ROS. Under normal circumstances (non-ﬁbrotic response) the
transient induction of inﬂammation by ROS is followed by tissue regeneration.family members are designated NOX1–5 and DUOX1/2 [33,34].
While the expression of NOX2 appears to be conﬁned to poly-
morphonuclear cells, macrophages and endothelial cells, NOX1
seems to be present in the plasma membrane of various cell types
[33,37,38]. In general, NOX activity is supposed to be tightly con-
trolled by regulatory subunits. Among these are the classical NOX2
regulators p47phox and p67phox, their homologs NOXO1 and
NOXA1, the DUOX1/2 regulators DUOXA1 and 2, and the GTPase
Rac.
NOX-derived ROS were found to be associated with ﬁbrosis in
several organs such as lung [39], heart [40] kidney [41], pancreas
[42], and liver [43–45]. From the NOX proteins NOX4 is unique in
that its activity depends on NOX4 expression levels [20,46] and
except p22phox does not require further regulatory proteins.
NOX4 was found to be associated with endothelial cell dysfunction
linked to conditions such as hypoxia known to cause further up-
regulation of NOX4 expression [47]. In respect to these ﬁndings
and in relation to the activity of the other NOX proteins, NOX4
appears to be the most direct link between oxidative stress, ROS
production and ﬁbrosis.6. TGF-β a key cytokine in the ﬁbrotic process: links to ROS
In addition to enhanced ROS levels, various chemokines and
growth factors are also crucial for the onset and progression of
ﬁbrosis. Among the chemokines and growth factors secreted, the
cytokine transforming growth factor-β (TGF-β) appears to be a key
mediator of the ﬁbrotic process, which plays a role in ﬁbrogenesis
in almost, if not all, organs [48–50]. Originally TGF-β was found to
be a potent inducer of anchorage-independent growth of human
embryonic kidney ﬁbroblasts [51]. In the meantime, three TGF-β
isoforms have been identiﬁed, which are called TGF-β1, TGF-β2
and TGF-β3. In most cases and until the three isoforms were dis-
covered, TGF-β refers to TGF-β1. In addition to ﬁbrosis, TGF-β1
plays also a role in various other diseases like Marfan syndrome,
Parkinson's disease, various cancers and diabetes (for review see
[52–54]). Importantly TGF-β1 is overexpressed in all ﬁbrotic tis-
sues, and it induces collagen production in cultured ﬁbroblasts
irrespective of their origin [55–58]. Increased evidence indicates
that production of ROS and oxidative stress are interlinked with
TGF-β1 production and activation and thus are key to the ﬁbrotic
process [21,59].
6.1. Production of ROS: involvement of TGF-β1
TGF-β1 was shown to promote ROS formation mainly via in-
duction of NOX4 expression and hence activity in various types of
cells [40,60–62]. The ROS produced in response to TGFβ1 are able
to activate various signaling pathways, thereby inﬂuencing gene
transcription networks downstream from TGF-β1 [21,41,63,64].
An important role for NOX4 was found in patients with idiopathic
pulmonary ﬁbrosis where NOX4 was selectively up-regulated in
the lungs and where it was associated with endothelial cell dys-
function and hypoxia which can cause a further up-regulation of
NOX4 expression [65,66]. In line, TGF-β1–dependent pro-ﬁbrotic
responses and ECM deposition in the lungs were inhibited by
siRNA-mediated NOX4 knockdown [39]. In line, mice deﬁcient in
NOX4 were found to be protected from bleomycin-induced acute
lung injury and the onset of ﬁbrosis [67]; mice deﬁcient for NOX2
were less protected from pulmonary ﬁbrosis [68]. Moreover,
therapeutic treatment with a low-molecular-weight NOX4 an-
tagonist attenuated the progression of a ﬁbrotic response in mice
with bleomycin-induced pulmonary ﬁbrosis [69]. A role of NOX4
was also established for liver ﬁbrosis where it was found to be
increased in patients with hepatitis C virus (HCV)-associated liver
Fig. 3. Generation of ROS and action of antioxidant enzymes The ROS superoxide (O2) is the major precursor for the production of other ROS (light gray); it is generated due
to the action of various enzymes. Antioxidant enzymes (dark gray) like superoxide dismutase (SOD) are able to convert O2 to H2O2 which can be neutralized through the
action of glutathione peroxidases (GPX), peroxiredoxins (Prx) or catalase (CTL). NOX, NADPH oxidase; XOR, xanthine oxidoreductase; COX, cyclooxygenase; NOS, nitric oxide
synthase; NO●, nitric oxide; ONOO● , peroxynitrite; NO2●, nitrogen dioxide; ●OH, hydroxyl radical; OH , hydroxide anion; Trx, thioredoxin; TrxR, thioredoxin reductase; GR,
glutathione reductase; GSH, glutathione; GSSG, oxidized glutathione.
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[70]. Further, the hepatic stellate cells (HSC) which are key in the
ﬁbrotic process of the liver responded to TGF-β1 with an induction
of NOX4-dependent ROS formation [71], The TGF-β-induced ﬁ-
brotic process was inhibited either by down-regulation of NOX4 or
in Nox4 /mice [72]. In addition to these data underlining the
role of NOX4, other studies indicated also the importance of NOX1
and NOX2 in the ﬁbrogenic process [45,73–75].
The so far dominant role of NOX4 in ﬁbrosis appears to be also
connected with aging since NOX4 was found to promote myoﬁ-
broblast differentiation and wound healing in young mice whereas
it promoted persistent ﬁbrosis in aged mice [39,64,76]. These ef-
fects in aged animals could be due to a loss of the antioxidant
response driven by the transcription factor NRF2 (nuclear factor-
erythroid 2 related factor 2) (see below). It was proposed that the
increase in the ratio between NOX4/NRF2 promotes ﬁbrosis and
development of senescent and apoptosis-resistant myoﬁbroblasts
in those aged mice [76]. Thus, it appears that TGF-β1 mediated
ROS production, mainly via NOX4, is crucially involved in the pa-
thogenesis of the ﬁbrotic response which is more severe and
persistent in elder subjects.Fig. 4. Involvement of ROS in TGF-ß mediated ﬁbrosis TGF-ß is released by different cell
macrophages). After the conversion from the latent to the active form, TGF-ß binds to its
through SMAD2/3 and/or PI3K. NOX4 expression leads to ROS production. Enhanced RO
epithelial-to-mesenchymal transition (EMT), apoptosis of epithelial cells and/or excess
hancement by decreasing the expression of antioxidant enzymes like glutaredoxin (G
superoxide dismutase (SOD) and the heavy subunit of gamma-glutamylcysteine synthe6.2. Reduction of ROS: involvement of TGF-β1
In addition to induction of expression of ROS producing en-
zymes, TGF-β1 may also suppress expression of several anti-
oxidant enzymes (Fig. 4). Under normal physiological conditions,
formation and removal of ROS are balanced to avoid oxidative
stress. In principle, an antioxidant can be any substance that de-
lays/prevents formation or promotes removal of ROS or oxidative
damage of a target molecule [32]. The antioxidant defense system
consists of a number of molecules among them glutathione (GSH)
and several enzymes, like superoxide dismutases (SODs), glu-
tathione peroxidases (GPXs), and catalase (CTL) represent major
players [32].
GSH is a three-residue peptide (γ-L-glutamyl-L-cysteinyl gly-
cine) which in the reduced state can donate an electron upon
which two molecules of GSH form the oxidized glutathione dis-
ulﬁde (GSSG). Glutathione reductase (GR) is able to reconvert
GSSG back to GSH. The ubiquitous presence of GSH in a high
concentration (1–10 mM) and this recycling system allow that it
acts as a major cellular antioxidant [77]. It can directly react with
O2̄ and some other ROS but more important are its indirect ROS-
scavenging functions [78–80]. These are achieved due to the in-
volvement of GSH in revitalizing other antioxidants; e.g. it can
reduce α–tocopherol radicals and semihydroascorbate radicalstypes like platelets, parenchymal cells, and inﬂammatory cells (e.g. lymphocytes,
receptor and induces expression of various genes, among them NOX4, via signaling
S may activate proliferation, migration and differentiation of ﬁbroblasts as well as
ive extracellular matrix deposition (ECM). Further, TGF-ß contributes to ROS en-
rx), catalase (CTL), glutathione peroxidase (GPX), glutathione S transferase (GST),
tase (gamma-GCSh).
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of hydrogen peroxidase. In addition, GSH is cofactor and substrate
for glutaredoxins and glutathione S transferase (GST) which con-
jugates reactive electrophilic compounds, including environmental
toxins, and products of oxidative stress, with GSH to detoxify them
[81].
Importantly, GSH levels were found to be decreased in patients
suffering from various ﬁbrotic diseases like chronic liver disease
and cirrhosis, viral hepatitis, chronic obstructive lung diseases and
asbestosis, conditions already reported to show increased ROS
levels [82–84]. Interestingly, alcohol consumption, a major reason
for chronic liver disease, did not only cause an 80–90% depletion of
GSH in liver but also in lungs [85]. Mechanistically the decrease in
GSH levels in liver cirrhosis could be explained by reduced pro-
duction. Thereby TGF-β1 appeared to be crucial since it affects the
function of gamma-glutamylcysteine synthetase (gamma-GCS),
the rate-limiting enzyme of GSH synthesis [86,87]. This enzyme
consists of the catalytical heavy (gamma-GCSh) subunit and the
regulatory light (gamma-GCSl) subunit. TGF-β1 decreased gamma-
GCSh expression in human lung alveolar epithelial cells [88] and in
the ﬁbrotic areas of usual interstitial pneumonia [89]. In addition,
the decrease in gammaGCSh and GSH levels along with increased
protein and lipid peroxidation due to TGF-β1 was also found in a
mouse model of lung ﬁbrosis [88]. Thus, the depletion of GSH in
response to TGF-β1 during ﬁbrosis may contribute to the appear-
ance of oxidative stress as seen during ﬁbrosis.
The function of GSH is closely associated with glutaredoxins
(Grx) which are thiol-disulﬁde oxidoreductases. Interestingly TGF-
β1 decreased Grx1 expression, again highlighting that the GSH
driven antioxidant system is of importance in ﬁbrotic lung dis-
eases [90,91].
Superoxide dismutases are another enzyme family with anti-
oxidant function. Three SODs catalysing all the dismutation of O2̄
to H2O2 and O2, but which are localized in the cytosol (SOD1),
mitochondria (SOD2), and extracellular (SOD3) can be dis-
tinguished. Moreover, the peroxisomal enzyme catalase is best
known to convert H2O2 to oxygen and water [32,92].
In addition, peroxiredoxins (Prx) have been shown to react
with H2O2 at an exceptionally high rate [93]. The action of Prx is
not restricted to H2O2 since Prx were also shown to reduce and
detoxify peroxynitrite and a wide range of organic hydroperoxides.
Like SODs, Prx members also display a different cellular location.
Prx1, 2 and 4 are mainly cytoplasmic but also found in nuclei; Prx1
is also present in mitochondria and peroxisomes while Prx4 is
found in lysosomes [94–96]. Mitochondria contain also Prx3, and
Prx5. In addition to mitochondria Prx5 is found in cytoplasm,
nuclei and peroxisomes [97]. It is believed that Prx2 because of its
high reaction rate and abundance traps almost all H2O2 in vivo
[79]. Oxidized Prx are reduced by thioredoxins (Trx) which can be
oxidized by the action of various stimuli [98]. Oxidized Trx (as well
as other oxidized cellular proteins) can be reversibly reduced by
thioredoxin reductase (TrxR) in a NADPH-dependent manner [98].
Again, Trx1 as well as TrxR1 can be found in the cytoplasm and
nucleus whereas Trx2 and TrxR2 are localized to mitochondria
[94,95].
Glutathione peroxidases from which GPX1 is the ubiquitous
memeber reducin cytosolic, mitochondrial and in some cells per-
oxisomal peroxides while GPX2 is an epithelial-speciﬁc form with
highest expression in intestine [99]. A secreted GPX3 form ex-
pressed in lung and kidney can be important in the protection
against external peroxides [99]. The fourth member GPX4 has
three isoforms derived from a single gene: cytosolic (c-GPX4),
mitochondrial (m-GPX4), and nuclear (n-GPX4) [100,101]. Unlike
other glutathione peroxidases, GPX4 has a broad range of sub-
strates; in addition to H2O2, these include derivatives from cho-
lesterol and cholesteroyl esters and thymine hydroperoxide [100].Overall, the conversion of H2O2 avoids formation of hydroxyl
radicals (OH) via an iron catalyzed Fenton reaction. In line, free
iron is sequestered by iron-binding proteins like ferritin and
transferrin to reduce intracellular ROS production. Dietary micro-
nutrients such as vitamin C, vitamin E, and minerals like selenium
as a component of peroxidases GPX1-4 and TrxRs are contributing
to the antioxidant activity [32].
Although not much is known about the particular role of the
antioxidant enzyme expression during ﬁbrosis, some cell culture
experiments have indicated a crucial role of TGF-β1 as a negative
regulator. It was shown that TGF-β1 inhibited the mRNA expres-
sion as well as the activities of GPX1 and CTL in a hamster pan-
creatic beta-cell line (HIT). Subsequently, the reduced expression
of these enzymes was associated with an increase in intracellular
ROS and oxidized proteins [102]. Furthermore, TGF-β1 also sup-
pressed the expression of SOD1, SOD2, CTL and GST in cultured rat
hepatocytes and in airway smooth muscle cells. Again, the reduced
expression of these antioxidant enzymes was associated with an
increase in cellular ROS levels [102–104].
Together, all the above mentioned ﬁndings suggest that the
ﬁbrotic action of TGF-β1 is coupled to an augmented production of
ROS due to induction of ROS generating systems and to suppres-
sion of antioxidant systems.7. NRF2 signaling in ﬁbrosis
As mentioned above the transcription factor NRF2 (nuclear
factor-erythroid 2 related factor 2) and its partner Keap1 (Kelch-
like ECH-associated protein 1) are considered to be the major
transcriptional regulators in the defense against ROS [105,106].
Thereby the sulfhydryl groups within Keap1 appear to be sensitive
to oxidant changes [105,107]. In the absence of ROS Keap1 is
bound to NRF2 and promotes its proteasomal degradation. Upon
an increase in ROS, the cysteine residues in Keap1, with Cys151
being the most critical, become oxidized and Keap1 can no longer
bind to NRF2. In addition, ROS induce a dephosphorylation of
Keap1 at Tyr141 which promotes Keap1 degradation [108]. As a
result, NRF2 is stabilized and transported to the nucleus; its nu-
clear presence is promoted due to ROS-dependent oxidation of
Cys183 which inhibits binding to the nuclear export protein CRM1.
Once in the nucleus NRF2 binds to a small Maf protein to activate
genes of the antioxidant response [105,107].
NRF2 signaling seems to be important for the pathogenesis of
ﬁbrosis since several studies have demonstrated that NRF2 /
mice are more susceptible to chemically induced oxidative stress
than wild-type mice; in particular in liver [109,110]. In the liver
NRF2 protects mice from carbon tetrachloride induced hepatic ﬁ-
brosis [111] and enhanced iron accumulation, steatosis, in-
ﬂammation and ﬁbrosis when fed a methionine-and choline-de-
ﬁcient diet [112–115]. Apparently, the NRF2 protective mechan-
isms become less efﬁcient with aging, which is expected to con-
tribute to disease progression [49]. Moreover, the NRF2 system
appeared also to be involved in mediating the defense against high
fat diets or chronic alcohol abuse. Clinical studies and experi-
mental models indicate that alcohol abuse increases the risk for
liver ﬁbrosis and cirrhosis as well as for acute lung injury. With
respect to the latter it was shown that chronic alcohol abuse in
mice primed the lung for bleomycin-induced ﬁbrosis [116]. The
alcohol ingestion further caused glutathione depletion and an in-
creased TGFβ-1 expression. In addition, the expression of the
NRF2-dependent antioxidant enzymes glutathione S-transferase
theta 2, and glutamate-cysteine ligase catalytic subunit were
found to be reduced. The effects of alcohol appeared to be medi-
ated via TGFβ 1 expression since blocking TGFβ 1 signaling atte-
nuated the alcohol-induced suppression of NRF2 [117].
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primarily regulated due to the sensitivity of Keap1, it became
evident that upstream or parallel regulatory circuits exist. For
example recent ﬁndings indicated that the selenoprotein thior-
edoxin reductase 1 (TrxR1) is a potent NRF2 regulator. Deﬁciency
of selenium and concomitant loss of TrxR1 reactivity is combined
with induction of NOX activity and oxidative stress [118].
Moreover, critical feed-forward responses also appear to exist
and one includes the NRF2-dependent expression of the tran-
scription factor Kruppel-like factor 9 (Klf9) when the levels of
intracellular ROS are above a critical threshold. The induction of
Klf9 results in further increases in ROS and subsequent cell death.
The importance of this mechanism for the pathogenesis of ﬁbrosis
was underlined by recent ﬁndings demonstrating that Klf9 in-
dependently increased ROS in-vitro and in-vivo in mice where it
promotes bleomycin-induced pulmonary ﬁbrosis. The effects of
Klf9 are achieved via its DNA binding function; it binds to pro-
moters and alters expression antioxidant genes like thioredoxin
reductase 2 [119].
Interestingly, a number of natural products are NRF2 activating
substances; among them the plants, fruits and vegetables com-
ponents quercetin, genistein, curcumin and sulforaphane; ther-
apeutics such as oltipraz, auranoﬁn and acetaminophen; en-
vironmental agents like paraquat, and metals as well as en-
dogenous substances like hydrogen peroxide, NO, or 4-hydro-
hynonenal [120]. This somehow may imply that an activation of
the NRF2 pathway may be of therapeutical beneﬁt. However,
Keap1 knockout mice die shortly after birth. This ﬁnding and the
rescue of this lethal phenotype in Keap1/ NRF2 double knockout
mice [121] suggests that excessive NRF2 activity may be detri-
mental for normal life and may render cellular behavior as in-
dicated by a study showing that constitutive activation of the NRF2
pathway is beneﬁcial for tumor survival [122]. Altogether, the
NRF2 system seems to be critically involved in the redox-depen-
dent regulation of ﬁbrosis, in particular due to its inactivation in
response to TGFβ1. However, due to the multilayered control steps
which are currently unraveled it becomes clear that the present
knowledge about NRF2 in ﬁbrosis is a piece of an interesting
puzzle.
7.1. Activation of TGF-β: involvement of ROS
As the name implies, TGF-β is not only an inducer of ROS
forming enzymes and suppressor of ROS degrading enzymes.
However, to become active TGF-β needs to be free since it nor-
mally exists in a latent complex where it is bound to two other
polypeptides, latent TGF-β binding protein (LTBP) and latency-
associated peptide (LAP). Although some aspects of the TGF-β
activation process are quite well known, the mechanisms are far
from being understood. Serum proteases such as plasmin and a
number of matrix metalloproteases as well as thrombospondin-1
can induce the release of TGF-β from the latent complex with LTBP
and LAP [123,124] In addition, integrins, pH, and ROS have been
shown to be able to activate TGF-β [125–127].
In particular the latter mechanism appears to be important
since enhanced levels of ROS are not only associated with ﬁbrosis
but also with a number of other diseases which display high TGF-
β1 levels like cancer and diabetes. This implies that ROS would
have the potential to activate TGF-β1 Indeed, recent studies from a
cell-free system in which ROS were generated in solution by io-
nizing radiation or metal ion-catalyzed ascorbate reactions in-
dicate that recombinant latent TGF-β1 can be activated directly by
ROS [127]. Thereby, the metal-catalyzed ascorbate oxidation
mediated TGF-β1 activation appeared to be very efﬁcient, and
dependent on ascorbate concentrations and presence of transition
metal ions. Moreover, the ROS dependent activation of TGF-β1appeared to be isoform speciﬁc and to be restricted to TGF-β1
particularly only oxidizing the LAP-beta1 protein at methionine
253 [127]. Together, ROS are not only a result of TGF-β action but
appear also to be crucial for the activation of TGF-β1 indicating
that they are causally involved in the ﬁbrogenic process.8. ROS, hypoxia, and ﬁbrogenesis
Changes in ROS levels are not only coupled to the action of
various chemokines, hormones, and growth factors but also as-
sociated with hypoxia which is a major sign of ﬁbrosis due to loss
of endothelial cells, rareﬁcation of capillaries and subsequent
malperfusion. The loss of endothelial cells may be due to en-
dothelial-mesenchymal transition (EndMT), a process where en-
dothelial cells undergo a transformation and acquire a mesench-
ymal (ﬁbroblast-like) phenotype. EndMT is dormant in the adult
organs, injuries, or inﬂammatory events which contribute to ﬁ-
brosis may reactivate this embryonic process [128–130]. TGF-β
and hypoxia are drivers of EndMT. Although hypoxia through ac-
tivation of hypoxia-inducible transcription factor-1α (HIF-1α)
[131,132] drives expression of endothelial growth factors to induce
angiogenesis with the aim to improve the capacity to regenerate
(or form new) vessels, the link to EndMT suggests that higher ﬁ-
broblast formation through hypoxia-driven EndMT will occur [57].
While injection of VEGF was beneﬁcial in some experimental
models of organ ﬁbrosis [133–135], a recent study demonstrated
that hypoxia is a stimulus for human coronary endothelial cells to
undergo EndMT via a HIF1-α driven mechanism. Thereby, HIF-1α
induced expression of the transcription factor Snail which is a
master regulator of EndMT [136]. Together, it is likely that hypoxia,
depending on the regenerative capacity of the injured tissue, may
contribute to vessel regeneration via HIF-driven VEGF or to pro-
gression of ﬁbrosis via Snail-driven EndMT.
8.1. ROS as post-transcriptional and epigenetic regulators in ﬁbrosis
Although our understanding in the pathogenesis of ﬁbrosis has
improved tremendously, a huge number of aspects remain still to
be resolved. One such aspect is the often occurring inter-individual
severity and progression of ﬁbrosis, and the responsiveness to
therapeutic regiments in different patients with similar underlying
diseases. The basis for the differences may lay in varying post-
transcriptional gene regulation events, genetic variability, and
epigenetic mechanisms [137].
Recently, microRNAs (miRNAs) which mediate post-transcrip-
tional regulation by promoting mRNA degradation and transla-
tional repression have been shown to be regulators of pro- and
anti-ﬁbrotic processes [138] (Fig. 5). TGF-β1 was also found to be a
powerful driver of miRNA expression. The link between ROS, ﬁ-
brosis and miRNA expression became especially evident in the
regulation of NOX4 expression. As mentioned earlier, TGF-β reg-
ulates the expression of NOX4, the major catalytic subunit of the
ROS generating NADPH oxidase NOX4. NOX4–dependent genera-
tion of hydrogen peroxide was required for TGF-β–induced myo-
ﬁbroblast differentiation, ECM production and contractility [39].
The so called “redoximiRs” miR-146a, and miR-25 [139] down-
regulate the expression of NOX4 and thus ROS generation whereas
miR-135b and miR-708 can be upregulated by H2O2. Moreover, the
expression of the major antioxidant transcription factor NRF2 can
be abrogated by miR-153, miR-27a, miR-142-5p, and miR144.
Further, the activity of NRF2 is inﬂuenced via the action of miR-
200a which targets Keap1, that represses NRF2, and via miR-34a
that targets sirtuin1 (Sirt1), deacetylates NRF2 and promotes its
nuclear export (for review see [139,140]). In addition, miR-433 was
shown to downregulate expression of the catalytic and regulatory
Fig. 5. Interconnection of ROS with miRNA expression and epigenetic modiﬁcations
MiRNAs are able to regulate ROS via post-transcriptional degradation of NOX4 and
Nrf2 mRNA. Further, ROS are associated with DNA hypermethylation causing de-
creased expression of different genes like O-6-methylguanine-DNA methyl-
transferase (MGMT), mutL homolog 1 (MLH1), thymocyte differentiation antigen-1
(Thy-1), Krüppel-like factor 4 (Klf4), methyl CpG binding protein 2 (MeCP2), RAS
protein activator like 1 (RASAL1), peroxisome proliferator-activated receptor (PPAR-
γ) and patched1 (PTCH1).
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GCS [141]. Another miRNA, miR-27a/b, was recently shown to
suppress the mitochondrial protein prohibitin 1, whose deﬁciency
results in downregulation of NRF2 [142] and appearance of NASH-
like symptoms and liver ﬁbrosis. Furthermore, miR-30e which
directly targets the mitochondrial protein UCP-2 was found to be
downregulated in ﬁbrotic kidneys [143]. Thus, miRNAs appear to
represent another link where redox signaling and regulatory me-
chanisms of ﬁbrosis converge.
Epigenetic changes, deﬁned as heritable traits that are not
linked to changes in DNA sequence, but where DNA methylation,
and post-translational modiﬁcations of histones and other chro-
matin-associated proteins regulate transcription [144], are another
basis for observed differences in ﬁbrosis. Epigenetic changes like
DNA methylation can also be inﬂuenced by ROS [145]. For ex-
ample, ROS-mediated DNA base modiﬁcations like 8-oxodG for-
mation adjacent to a cytosine may prevent methylation of the
latter [146]. The resulting hypomethylation may contribute to in-
duction and suppression of gene expression thus enabling the cells
to achieve novel characteristics which may contribute to tumor-
igenesis. ROS are also associated with hypermethylation [145] that
can lead to increased overall mutation rates by downregulating
expression of repair genes like O-6-methylguanine-DNA methyl-
transferase and MLH1 (mutL homolog 1) [147]. Although a direct
link to ROS has not been shown, hypermethylation of phosphatase
and tension homolog (PTEN) with consequent gene repression
favoring ERK and AKT signaling, cell proliferation and migration
appears to promote liver ﬁbrosis [148]. Hypoxia-induced DNA
hypermethylation in human pulmonary ﬁbroblasts was found to
be associated with Thy-1 promoter methylation and the develop-
ment of a pro-ﬁbrotic phenotype [149] and Tet3-mediated silen-
cing of genes due to hydroxymethylation contributed to bone
morphogenic protein 7-induced reversal of kidney ﬁbrosis [150].
In addition, hypermethylation and repression of Krüppel-like fac-
tor 4 through Dnmt1 [151], and hypermethylation of (methyl CpGbinding protein 2 (MeCP2) [152], RAS Protein Activator Like 1
(RASAL1) [153], peroxisome proliferator-activated receptor (PPAR-
γ) [154], and patched1 (PTCH1) [152] appear also to promote
ﬁbrosis.
While epigenetic modiﬁcations in general are acquired in re-
sponse to environmental stimuli, recent evidence links epigenetic
modiﬁcations in three regions of the SOD2 gene with loss of SOD2
activity and a feed-forward mechanism promoting further epige-
netic aberrancies [155–157]. Thereby, increased O2 promotes
generation of further ROS with the result that a number of me-
tabolites critical for maintaining the cell homeostasis such as NAD
(þ), S-adenosyl methionine, and 2-oxoglutarate are altered. Since
these metabolites are critical cofactors for enzymes like sirtuins,
histone methyltransferases, and histone demethylases as well as
DNA demethylases, respectively, ﬂuctuations in these metabolites
may thus have direct effects on the epigenetic landscape with the
consequence of changes in gene expression [157]. Although the
direct link of an epigenetic silencing of SOD2 in ﬁbrosis remains to
be determined, it appears to be obvious that loss of SOD2 activity
promotes further epigenetic aberrancies which may be detri-
mental for a progression of cells from a ﬁbrotic into a cancer
phenotype.9. Fibrosis and beyond: antioxidants as treatment options?
Fibrosis frequently develops as an own entity on the basis of
most common pro-ﬁbrotic co-morbidities like obesity, diabetes,
non-alcoholic fatty liver disease) chronic kidney disease, idio-
pathic pulmonary ﬁbrosis, or cardiomyopathy and is a key de-
terminant for progression into diseases like liver cirrhosis, end-
stage renal disease, lung ﬁbrosis or even cancer. These diseases are
to a large extend associated with a “Western life style” where
dietary caloric intake has increased and energy expenditure has
been reduced. Moreover, a lot of changes in the food composition
with polyunsaturated fatty acids, excess proteins and cereals have
been observed. In addition, chronic alcoholism and tobacco
smoking increased severely keeping pace with ever worsening
environmental toxicity. Thus, our established antioxidant cap-
ability is confronted with more difﬁculties than it is supposed to
encounter, underpinning, at least in part, increased occurrence of
the above mentioned diseases and ﬁbrosis.
In light of this, it could be imagined that supplementation of
diets with antioxidants would be a therapeutic option. This could,
in addition to therapies speciﬁc to the underlying disease, and
inhibition of TGF-β signaling, be helpful in terms of ﬁbrosis.
However, the expectations which were already put into the role of
antioxidants and their health beneﬁcial effects could not be met.
With respect to lung ﬁbrosis and respiratory diseases like asthma
or chronic obstructive pulmonary disease, recent evidence sug-
gested the therapeutic use of resveratrol, a natural antioxidative
polyphenol present in grapes and various berries. However,
though the in vitro and animal data would support resveratrol use,
large clinical trials need to be performed to estimate its real
beneﬁt [158]. Moreover, recent meta-analyses of clinical studies
analyzing the effects of β-carotene, vitamin A, and vitamin E on
mortality indicate that nutrient supplementation with the “anti-
oxidants” is paradoxically rather health threatening than bene-
ﬁcial since a high intake of these substances either as a single
compound or in different combinations, had no beneﬁcial effects
[159]. In particular, vitamin A was even found to be associated
with increased mortality [160–162]. Moreover, large scale studies
with respect to cancer and nutritional supplementation with
particular antioxidants also showed that the outcome is quite
heterogeneous. The risk for cancer might be prevented or delayed
by using a selective diet preferentially from an early stage of life;
K. Richter et al. / Redox Biology 6 (2015) 344–352 351thereby a balanced energy intake and expenditure as well as in-
dividual genetic predispositions have to be considered. In line,
analyses of antioxidant treatment in multicenter patient trials of
idiopathic lung ﬁbrosis showed also no or only modest beneﬁcial
effects [163–165]. Although ROS seem to have an important role in
ﬁbrosis, these studies make it difﬁcult to interpolate and to make
any further prediction/recommendation in terms of antioxidant
therapy. However, the low evidence from the large scale studies
available so far, indicates the demand to further increase our
knowledge about the interconnection between nutrition, lifestyle
and the dynamics of ROS/antioxidant action as well as to improve
and to standardize techniques measuring reliable biomarkers in
terms of ﬁbrosis and underlying diseases.Acknowledgments
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